WO2011152618A4 - 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 - Google Patents
국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 Download PDFInfo
- Publication number
- WO2011152618A4 WO2011152618A4 PCT/KR2011/003547 KR2011003547W WO2011152618A4 WO 2011152618 A4 WO2011152618 A4 WO 2011152618A4 KR 2011003547 W KR2011003547 W KR 2011003547W WO 2011152618 A4 WO2011152618 A4 WO 2011152618A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- botulinum toxin
- fraction
- pii
- sub
- purified
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
Definitions
- the present invention relates to a method of purifying non-proliferative botulinum toxin and to a non-proliferative botulinum toxin having the effect of local paralysis obtained thereby.
- Botox is widely used for treating cerebral palsy muscles as well as treating pain caused by rigid neck muscles, facial muscle stiffness, and vocal fold paralysis.
- it is used for wrinkle removal and anti-aging treatment.
- anti-aging medicine has become popular, and the use of botox is increasing every year.
- Botox is injected into the muscles to paralyze the muscle nerves. This has resulted in the treatment of children with cerebral palsy, in which leg muscles are excessively rigid, injecting Botox to naturally gait.
- the FDA has reported that Botox toxin is spreading to other parts of the body in addition to the legs, affecting respiratory muscle function and causing side effects [FDA NEWS RELEASE FOR IMMEDIATE RELEASE April 30, 2009, FDA Patient Safety News: Show # 74, April 2008].
- FDA-approved Patient Labeling 7/31/09 APPENDIX 1 MEDICATION GUIDE BOTOX, FDA-approved Patient Labeling," said FDA.
- Patients and doctors need to be careful about breathing slowness or difficulty swallowing after Botox, BOTOX Cosmetic (Boe-tox) (on a botulinum toxin A) for Injection)].
- botulinum toxin purified by the above-mentioned method has a considerable amount of the toxin spread to other parts of the body, resulting in paralysis of peripheral organs or respiratory muscles, and serious side effects leading to death in severe cases.
- the present invention has been proposed in order to solve the above problems.
- An existing botulinum toxin type A preparation purified by chromatography after acid precipitation or acid precipitation is subjected to anion ion exchange resin chromatography using sodium chloride, And one of the subfractions was confirmed to have myofilmic activity, but not in the body.
- the object of the present invention is to provide a non-proliferative botulinum toxin having a local non-proliferative but locally limited muscular activity and a method for separating the same.
- the present invention provides a method of purifying a non-proliferating botulinum toxin, comprising the steps of adjusting the purified botulinum toxin type A preparation to a pH of 4.5 to 6.5 and a concentration of sodium chloride (NaCl) of 0.02 to 0.2 M Separating the sub-fractions by performing anion exchange resin chromatography added thereto; And obtaining a non-proliferative botulinum toxin fraction wherein the value of A260 / A280 in the sub-fraction is maintained at a level of 0.4 to 0.6.
- the non-proliferative botulinum toxin of the present invention is isolated and purified by the above-mentioned method, wherein at least 150 ppb of Zn ion, at least 80 ppb of Fe ion, and at least 140 ppb of Mg ion per 100 U / As shown in FIG.
- the present invention provides a method for distinguishing a non-proliferative botulinum toxin from a non-proliferative botulinum toxin in an amount of 1.5 to 3 times its half-life lethal dose, And judging whether the respiratory muscle is paralyzed or not.
- a non-proliferative botulinum toxin having high toxin-to-protein titer for each production batch can be obtained.
- a large amount of non-multiplying botulinum toxin that does not mix with diffusible toxins can be obtained by controlling anion chromatography conditions.
- Fig. 1 is a result of ionic resin chromatography showing the result of separating sub-fractions according to Example 1.
- FIG. 2 is a graph showing the change in sub-peak% by the pH change of the buffer.
- FIG. 3 is a graph showing changes in% peak fraction of each subunit according to the sample sample.
- FIG. 5 is a photograph showing the in vivo diffusibility of the undifferentiated active fraction (pII) in the sub-fraction isolated according to Example 1 and the existing commercially available product in the right lower limb after administration for 12 hours.
- FIG. 6 shows the survival rates according to the dose (A) and the post-administration time (B) after administration of the undifferentiated active fraction (pII) in the sub-fraction isolated according to Example 1 and the existing commercial product to the right lower limb of the mouse Graph.
- FIG. 7 is a graph comparing the onset time of the muscle paralysis effect in the right lower limb of the non-spontaneous active fraction (pII) in the sub-fraction isolated by Example 1 and 1 U of the conventional commercial product.
- FIG. 8 is a graph comparing the duration of muscle paralytic effect after administration to the right lower limb of the non-spontaneously active fractions (pII) of the sub-fractions separated by Example 1 and 0.5 U of the conventional commercial product.
- NaCl sodium chloride
- the method for purifying the non-proliferative botulinum toxin of the present invention is a method of purifying the botulinum toxin obtained by using the existing acid precipitation method or acid precipitation after ion precipitation by using the new anion ion exchange resin chromatography method proposed by the inventors of the present invention To obtain a fraction of the non-proliferating botulinum toxin.
- the method for purifying the non-spreading botulinum toxin of the present invention comprises the steps of acid precipitation of the botulinum toxin type A formulation from Clostridium botulinum type A culture broth, or separation and purification of the botulinum toxin type A by chromatography after acid precipitation, Use a toxin type A formulation.
- the buffer used to carry out the anion ion exchange resin chromatography is sodium acetate buffer, and each fraction which is separated by sequentially increasing the sodium chloride concentration added to obtain the sub-fraction is taken.
- the sodium chloride was not used (concentration 0 M NaCl)
- the fraction isolated was a diffusible active fraction (peak I, pI) in the body.
- the concentration of sodium chloride used to obtain the pII is in the range of 0.02 to 0.2 M, and when no sodium chloride is used, or when the concentration of sodium chloride is higher or lower than the above range, pI or pIII fraction It is difficult to obtain a non-proliferative active fraction having a local muscle palsy effect, which is the object of the present invention.
- the purified botulinum toxin type A preparation reagent is performed in the range of 1/5 to 1 times the volume of the anion ion exchange resin chromatography column used, . That is, when the volume of the column is 1 ml and the amount of the purified botulinum toxin type A pharmaceutical preparation is 0.2 to 1 ml, the fraction of pII obtained is in the range of 20% to 50%.
- the pII fraction obtained by the method of purifying the non-multiplying botulinum toxin of the present invention was found to be stable such that the half-life lethal dose (total LD50) confirmed by using a mouse was 1 ⁇ 10 5 to 5 ⁇ 10 5 U / ml .
- the half-life lethal dose (total LD50) confirmed by using a mouse was 1 ⁇ 10 5 to 5 ⁇ 10 5 U / ml .
- the onset of muscle paralysis was significantly faster and the duration of muscle paralysis was longer than that of the commercial product.
- the non-proliferating botulinum toxin (pII fraction) obtained by the method of purifying the non-proliferating botulinum toxin of the present invention contains at least 150 ppb Zn ions, at least 80 ppb Fe ions and at least 140 ppb Mg ions per 100 U / ml of toxin do.
- the method for purifying the non-proliferative botulinum toxin of the present invention is characterized in that the content of Mg, Fe and Zn is significantly higher than that of the botulinum toxin type A purified by the conventional method.
- the non-proliferative botulinum toxin obtained by the present purification method of the present invention is 1.5 to 3 times the lethal dose of the non-proliferative botulinum toxin obtained by the present invention, and when injected into the right lower limb of the mouse, the right lower limb muscle paralyzes, but does not have paralysis or lethal activity of the respiratory muscle , Thereby determining whether or not the non-spreading botulinum toxin of the present invention is diffused.
- a commercially available product used in Examples of the present invention is Botox preparation (Lot #: Allergan, Inc.) manufactured by the method disclosed in USP 7,354,740 (Animal product free system and process for purifying botulinum toxin) C2066 C2, C2481 C2) or the botulinum toxin type A preparation purified by a commercially available product or method described in the present invention, but it is not sufficient if it can be used as a purified botulinum toxin type A preparation by other acid precipitation or the like .
- Fig. 1 [pI, Peak I Fraction); pII, Peak II (in vivo non-active active fraction); pIII, PeakIII (inactive fraction)].
- the used column is Hitrap DEAE FF 1 ml (GE healthcare, Cat # 17-5055-01), and the buffer used is running buffer (running buffer) running buffer, sodium acetate buffer (pH 5.5), and elution buffer.
- the peak% of the sub-fraction according to the change in the pH of the buffer used in the anion ion exchange chromatography is shown in FIG. As shown in FIG. 2, when the pH of the buffer is in the range of 4.5 to 5.5, the peak% of pII is increased.
- the A260 / A280 of the sub-fraction according to the pH of the buffer is shown in the following Table 1, and the half-life lethal dose (Total LD50 (Unit)) is shown in Table 2 below.
- pH of the buffer may be adjusted to 4.5 to 5.5 in order to obtain a purified, in-vivo unspent active fraction (pII).
- the half-life lethal dose is 0.8 ⁇ 10 5 to 3.5 ⁇ 10 5 U / ml, which means that the recovery rate of pII is high.
- the sub-fractions were obtained in the same manner as in Example 1, and the change in the peak characteristics of the sub-fractions (pI, pII and pIII) due to the change in the amount of the sample for this purpose is shown in Fig. 3.
- the change in A260 / A280 (Total LD50 (Unit)) is shown in Table 4 below.
- A260 / A280 appears to be 0.4 to 0.6 when the range of the therapeutic agent is in the range of 0.25 to 2 ml, and thus it can be judged to be suitable as the administration sample.
- the range of the treatment volume is 1/5 to 2 times the column volume.
- the half-life lethal dose is 0.8 ⁇ 10 5 to 3.5 ⁇ 10 5 U / ml, which indicates that the recovery rate of pII is high.
- mice used (ICR mouse, female, 4week, 18 ⁇ 22g) were 10 mice per experimental group, and the mouse weights were accurately measured and recorded.
- the 50 ⁇ l Hamilton syringe was filled with the sub-fraction at a concentration of 1 U / 20 ⁇ l without air to fit the unit, and the needle was injected into the muscle 3 cm from the ankle of the right hind leg of the ICR mouse.
- the paralysis index and the degree of death were observed according to the paralysis index and the measurement standard shown in the following Table 5, and the results are shown in FIG.
- Table 5 Score Dimensions 0 The appearance of the foot of a normal rat and gait One The toes are not gathered, but they turn off their legs when they walk. 2 The toes are gathered together with the criteria of 1. 3 The foot node bends inward with the criteria of 2. 4 With the criteria of 3, the foot is fully attached to the leg muscles and the leg is not worn.
- the non-spontaneous active fractions (pII) of the sub-fractions isolated in Example 1 showed a significant increase in survival rate compared to the dose-dependent active fractions (pI) (A)
- the survival rate over time at 2U of dose showed an extreme difference of pI 0% versus pII 100% (B).
- mice used were 10 mice per experimental group, and the mouse weights were accurately measured and recorded.
- a 50 ⁇ l Hamilton syringe was filled with the pre-purification sample and sub-fraction pII at a concentration of 1 U / 20 ⁇ l, without air to the unit, and injected into the muscle 3 cm from the ankle of the right hind leg of the ICR mouse.
- the degree of paralysis of the mouse was visually confirmed, and the state of the mouse after 12 hours from the injection was shown in FIG. 5, The results are shown in Fig.
- the onset time of the muscle paralysis effect is shown in FIG. 7, and the duration of the muscle paralysis effect is shown in FIG.
- pII is injected intramuscularly but paralyzed, but conventional commercial products have been shown to have spread to the waist and opposite legs and paralyzed.
- pII showed a significant increase in survival rate as compared with the commercial product (A), and the survival rate over time at a dose of 2 U was significantly higher than the pII of 100% (B).
- the duration of the muscle palsy effect was longer than that of the commercially available product at a dose of 0.5 U, which was longer than 80 days.
- the pII fraction was diluted, and the same amount of botulinum toxin (100 U) and ancillary additives were injected and lyophilized, and the activity between commercial product and pII lyophilisate was identical And then analyzed for ion content.
- the two freeze-dried products were dissolved in distilled water (10 ml), and the ion content was measured using an inductively coupled plasma mass spectrometer. The results are shown in Table 7 below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Virology (AREA)
Abstract
Description
A260/A280 | ||||
pH 4.5 | pH 5.0 | pH 5.5 | pH 6.0 | |
pI | 0.76± 0.15 | 0.69± 0.09 | 0.67± 0.05 | 0.63± 0.08 |
pII | 0.50± 0.05 | 0.55± 0.04 | 0.55± 0.03 | 0.81± 0.19 |
pIII | 0.76± 0.10 | 0.82± 0.13 | 0.84± 0.12 | 0.79± 0.09 |
Total LD50(Unit) | ||||
pH 4.5 | pH 5.0 | pH 5.5 | pH 6.0 | |
기존 산침전법 정제물(전시료) | 5± 0.8 | 5± 1 | 5± 0.8 | 5± 1.2 |
pI | 1.5± 0.4 | 3± 0.5 | 2± 0.4 | 2± 0.8 |
pII | 0.2± 0.2 | 1± 0.2 | 3± 0.4 | 0.4± 0.2 |
pIII | - | 0.2± 0.1 | 0.2± 0.1 | 2± 1 |
(단위: 105 U) |
A260/A280 | ||||
0.25 ml | 0.5ml | 1ml | 2ml | |
pI | 0.67± 0.08 | 0.64± 0.07 | 0.68± 0.09 | 0.67± 0.13 |
pII | 0.55± 0.02 | 0.56± 0.01 | 0.55± 0.04 | 0.55± 0.03 |
pIII | 0.85± 0.14 | 0.84± 0.09 | 0.82± 0.18 | 0.84± 0.24 |
Total LD50(Unit) | ||||
0.25 ml | 0.5 ml | 1 ml | 2 ml | |
기존 산침전법 정제물(전시료) | 2.5± 0.5 | 5± 1 | 10± 4 | 20± 5 |
pI | 0.8± 0.2 | 1.6± 0.4 | 5± 2 | 15± 4.8 |
pII | 1.6± 0.2 | 4± 0.6 | 4± 0.9 | 4± 1.5 |
pIII | 0.2± 0.1 | 0.4± 0.1 | 0.8± 0.2 | 0.6± 0.3 |
(단위: 105 U) |
Score | 측정 기준 |
0 | 정상 쥐의 발 모양새와 걸음걸이 |
1 | 발가락은 모아지지 않았으나 걸을 때 다리를 끈다. |
2 | 1의 기준과 함께 발가락이 모아져 있다. |
3 | 2의 기준과 함께 발마디가 안쪽으로 굽어있다. |
4 | 3의 기준과 함께 발이 다리근육쪽으로 완전히 붙어있으며 다리를 못 쓴다. |
분획 | 마우스 우하지주사시 마비부위 |
체내 확산형 활성 분획 | 우하지, 횡경막, 좌하지 등 체내 여러 부위 |
체내 비확산형 활성 분획 | 우하지 |
체내 확산형 비활성 분획 | - |
Mg | Fe | Zn | |
pII | 183.0 ± 19.3* | 105.4 ± 22.1** | 332.6 ± 140.8*** |
시판제품 | 78.1 ± 7.4* | 39.6 ± 3.3 | 65.6 ± 25.9 |
* p<0.0015, ** p<0.011, ***p<0.045 |
Claims (3)
- 정제된 보툴리눔 독소 A 형 제제를 pH는 4.5 내지 6.5 범위, 염화나트륨(NaCl)의 농도를 0.02 내지 0.2M로 조절하여 첨가한 음이온 이온교환수지 크로마토그래피를 수행하여 아분획을 분리하는 단계; 및상기 아분획 중 A260/A280의 값이 0.4 내지 0.6 수준을 유지하는 비확산성 보툴리눔 독소 분획을 수득하는 단계를 포함하여 이루어지는 것을 특징으로 하는 비확산형 보툴리눔 독소의 정제방법.
- 청구항 1에 의하여 분리 정제된 것으로,독소 100U/ml당 Zn 이온이 적어도 150ppb, Fe 이온이 적어도 80ppb, Mg 이온이 적어도 140ppb로 포함되는 것을 특징으로 하는 비확산형 보툴리눔 독소.
- 청구항 2의 비확산형 보툴리눔 독소를 그의 반수치사량의 1.5 내지 3배의 양으로 마우스 우하지에 주사하고, 우하지 근육과 호흡근의 마비 여부와 치사여부를 판단하는 것을 특징으로 하는 비확산형 보툴리눔 독소를 판별하는 방법.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013513102A JP5919608B2 (ja) | 2010-05-31 | 2011-05-13 | 局所筋麻痺効果を有する非拡散型ボツリヌス毒素とその精製方法 |
CN201180028634.2A CN102985102B (zh) | 2010-05-31 | 2011-05-13 | 引起局部肌麻痹的非扩散型肉毒杆菌毒素及其精制方法 |
AU2011262499A AU2011262499B2 (en) | 2010-05-31 | 2011-05-13 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
ES11789976.5T ES2659820T3 (es) | 2010-05-31 | 2011-05-13 | Toxina botulínica no difusiva que provoca una parálisis muscular localizada y procedimiento de purificación de la misma |
EP11789976.5A EP2578228B1 (en) | 2010-05-31 | 2011-05-13 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
US13/700,867 US9598683B2 (en) | 2010-05-31 | 2011-05-13 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
US15/422,083 US20170145399A1 (en) | 2010-05-31 | 2017-02-01 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
US15/422,129 US10369235B2 (en) | 2010-05-31 | 2017-02-01 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0051076 | 2010-05-31 | ||
KR1020100051076A KR101134146B1 (ko) | 2010-05-31 | 2010-05-31 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/700,867 A-371-Of-International US9598683B2 (en) | 2010-05-31 | 2011-05-13 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
US15/422,129 Division US10369235B2 (en) | 2010-05-31 | 2017-02-01 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
US15/422,083 Division US20170145399A1 (en) | 2010-05-31 | 2017-02-01 | Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2011152618A2 WO2011152618A2 (ko) | 2011-12-08 |
WO2011152618A9 WO2011152618A9 (ko) | 2012-03-22 |
WO2011152618A3 WO2011152618A3 (ko) | 2012-05-24 |
WO2011152618A4 true WO2011152618A4 (ko) | 2012-07-12 |
Family
ID=45067165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/003547 WO2011152618A2 (ko) | 2010-05-31 | 2011-05-13 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
Country Status (8)
Country | Link |
---|---|
US (3) | US9598683B2 (ko) |
EP (1) | EP2578228B1 (ko) |
JP (2) | JP5919608B2 (ko) |
KR (1) | KR101134146B1 (ko) |
CN (1) | CN102985102B (ko) |
AU (1) | AU2011262499B2 (ko) |
ES (1) | ES2659820T3 (ko) |
WO (1) | WO2011152618A2 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
KR101775682B1 (ko) * | 2015-11-30 | 2017-09-06 | 주식회사 대웅 | 보툴리눔 독소의 제조방법 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE303567B (ko) * | 1959-02-17 | 1968-09-02 | Behringwerke Ag | |
US3409605A (en) * | 1965-06-15 | 1968-11-05 | American Cyanamid Co | Concentration and purification of growth factor-placental origin (human) |
WO1996005222A1 (en) * | 1994-08-08 | 1996-02-22 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
US5939070A (en) * | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
AU2340299A (en) * | 1998-01-26 | 1999-08-09 | University Of Massachusetts | Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
GB9921592D0 (en) * | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
KR100455280B1 (ko) | 2000-06-28 | 2004-11-08 | 삼성코닝 주식회사 | 인듐 틴 옥사이드(ito)의 제조방법 |
DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
JP2003009897A (ja) * | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
KR20030060150A (ko) * | 2002-01-07 | 2003-07-16 | (주)메디톡스 | 클로스트리디움 보툴리눔 a형 독소를 정제하는 방법 |
AU2003221050A1 (en) * | 2002-03-29 | 2003-10-13 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Remedy for hypermyotonia |
US6673598B1 (en) * | 2002-10-29 | 2004-01-06 | Synthecon, Inc. | Disposable culture bag |
US7160699B2 (en) * | 2003-09-25 | 2007-01-09 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
US7452697B2 (en) * | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
US7148041B2 (en) * | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
KR20050074806A (ko) * | 2004-01-14 | 2005-07-19 | 팜텍(주) | 결정형 보툴리늄 독소의 제조방법 |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7064639B2 (en) * | 2004-07-30 | 2006-06-20 | Delta Systems, Inc. | Electromagnetic latching switch |
BRPI0508374A (pt) | 2005-03-03 | 2007-07-31 | Allergan Inc | meios para bactéria clostrìdio e processo para obtenção de uma toxina clostrìdica |
US7465457B2 (en) * | 2005-04-14 | 2008-12-16 | Wisconsin Alumni Research Foundation | Method for preparing botulinum neurotoxin type A light chain |
JP4920583B2 (ja) | 2005-06-03 | 2012-04-18 | ライオン株式会社 | 脂肪酸低級アルキルエステルおよび軽油代替燃料 |
JP4979690B2 (ja) * | 2006-04-28 | 2012-07-18 | 一般財団法人化学及血清療法研究所 | 神経毒素の定量方法 |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
PT2085093E (pt) * | 2006-10-27 | 2015-06-26 | Chemo Sero Therapeut Res Inst | Preparação que contém uma toxina botulínica tipo a altamente purificada derivada de um agente patogénico do botulismo infantil |
CN101204577A (zh) * | 2006-12-21 | 2008-06-25 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种a型肉毒毒素结晶复合物的制备方法 |
KR101025617B1 (ko) | 2008-02-25 | 2011-03-30 | 메덱스젠 주식회사 | 클로스트리디움 보툴리눔으로부터 보툴리눔 독소를정제하는 방법 |
KR20090120222A (ko) * | 2008-05-19 | 2009-11-24 | (주)메디톡스 | 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법 |
KR102005930B1 (ko) * | 2008-12-31 | 2019-07-31 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
US8440204B2 (en) * | 2009-04-30 | 2013-05-14 | Wisconsin Alumni Research Foundation | Subtype of Closteridium botulinum neurotoxin type A and uses thereof |
US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
PT2490986T (pt) * | 2009-10-21 | 2018-11-13 | Revance Therapeutics Inc | Métodos e sistemas para purificar neurotoxina botulínica não complexada |
EP2512519A2 (en) * | 2009-12-18 | 2012-10-24 | Allergan, Inc. | Clostridium botulinum carrier complex for the administration of therapeutic agents |
US8546108B2 (en) * | 2010-01-25 | 2013-10-01 | Allergan, Inc. | Methods of intracellular conversion of single-chain proteins into their di-chain form |
KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
JP6061853B2 (ja) * | 2010-07-30 | 2017-01-18 | メディミューン,エルエルシー | 活性ポリペプチドまたは免疫複合体の精製方法 |
-
2010
- 2010-05-31 KR KR1020100051076A patent/KR101134146B1/ko active IP Right Grant
-
2011
- 2011-05-13 CN CN201180028634.2A patent/CN102985102B/zh not_active Expired - Fee Related
- 2011-05-13 EP EP11789976.5A patent/EP2578228B1/en not_active Revoked
- 2011-05-13 AU AU2011262499A patent/AU2011262499B2/en not_active Ceased
- 2011-05-13 WO PCT/KR2011/003547 patent/WO2011152618A2/ko active Application Filing
- 2011-05-13 US US13/700,867 patent/US9598683B2/en not_active Expired - Fee Related
- 2011-05-13 JP JP2013513102A patent/JP5919608B2/ja not_active Expired - Fee Related
- 2011-05-13 ES ES11789976.5T patent/ES2659820T3/es active Active
-
2015
- 2015-05-07 JP JP2015094777A patent/JP5998419B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-01 US US15/422,083 patent/US20170145399A1/en not_active Abandoned
- 2017-02-01 US US15/422,129 patent/US10369235B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102985102B (zh) | 2016-06-08 |
US9598683B2 (en) | 2017-03-21 |
EP2578228A4 (en) | 2013-10-02 |
JP5998419B2 (ja) | 2016-09-28 |
ES2659820T3 (es) | 2018-03-19 |
US20170143849A1 (en) | 2017-05-25 |
JP5919608B2 (ja) | 2016-05-18 |
WO2011152618A9 (ko) | 2012-03-22 |
US20130071331A1 (en) | 2013-03-21 |
WO2011152618A3 (ko) | 2012-05-24 |
EP2578228B1 (en) | 2017-11-15 |
US20170145399A1 (en) | 2017-05-25 |
JP2015200659A (ja) | 2015-11-12 |
JP2013533856A (ja) | 2013-08-29 |
AU2011262499A1 (en) | 2013-01-24 |
EP2578228A2 (en) | 2013-04-10 |
CN102985102A (zh) | 2013-03-20 |
KR101134146B1 (ko) | 2012-04-19 |
WO2011152618A2 (ko) | 2011-12-08 |
KR20110131572A (ko) | 2011-12-07 |
AU2011262499B2 (en) | 2015-01-22 |
US10369235B2 (en) | 2019-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tamminga et al. | Des-tyrosine-γ-endorphin administration in chronic schizophrenics: A preliminary report | |
WO2021204170A1 (zh) | 一种中华冀土鳖虫来源的具有降血脂功能的活性肽及其制备方法和应用 | |
CN107213149B (zh) | 青蒿素类衍生物在制备治疗或辅助治疗自身免疫性甲状腺疾病药物中的用途 | |
WO2010030755A1 (en) | Methods of using sustained release aminopyridine compositions | |
Nie et al. | Inhibition of mammalian target of rapamycin complex 1 signaling by n-3 polyunsaturated fatty acids promotes locomotor recovery after spinal cord injury | |
WO2011152618A4 (ko) | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 | |
WO2012033235A1 (ko) | N-아세틸-l-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물 | |
CN110772631A (zh) | 一组与烟碱乙酰胆碱受体具有高度亲和力能快速起效的眼镜蛇神经毒素分子在镇痛上的应用 | |
Liu et al. | Intravenous Administration of Vitamin C in the Treatment of Herpes Zoster‐Associated Pain: Two Case Reports and Literature Review | |
CN104546928A (zh) | 一种治疗小儿尿布疹的中药组合物及其制备方法 | |
ALfaifi et al. | Cobra snakebite mimicking brain death treated with a novel combination of polyvalent snake antivenom and anticholinesterase | |
WO2022097764A1 (ko) | 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물 | |
CN109925342B (zh) | 痰热清在制备脑胶质瘤治疗药物中的新用途 | |
CN109718253A (zh) | 一种代谢产生组胺的菌在预防或治疗高原病中的用途 | |
CN1261105C (zh) | 一种复方吡拉西坦脑蛋白水解物制剂及制备方法 | |
WO2020141778A1 (ko) | 세리신을 포함하는 지방간 치료, 예방, 또는 완화용 조성물 및 상기 조성물의 제조 방법 | |
CN102204975B (zh) | 一种治疗急、慢性肠炎的药物组合物 | |
CN108096243A (zh) | 银杏内酯组合物的医药用途 | |
CN109172578B (zh) | 磷酸哌喹在制备治疗脂类代谢紊乱和高血脂症药物中的应用 | |
Barnes et al. | Disturbed behavior induced by high-dose antipsychotic drugs. | |
CN106539816A (zh) | 环二核苷酸在防治多发性硬化症中的应用 | |
US20230277588A1 (en) | Compositions and methods for treating pain with extracellular vesicles | |
CN106361737A (zh) | 曲尼司特在制备治疗结核病的药物中的应用 | |
Guida et al. | ORCID ID 0000-0003-1027-7049. Genetic Polymorphism in Porphyria: Resolution of A Case of Tetraplegia by Administration of Hemin During a Porphyric Crisis and Subsequent Therapeutic Procedure with the use of Givosiran | |
Batbayar et al. | DETERMINATION OF SOME ORGANIC ACIDS IN “BARAGSHUN EN” PREPARATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180028634.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11789976 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2013513102 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13700867 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011789976 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011789976 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011262499 Country of ref document: AU Date of ref document: 20110513 Kind code of ref document: A |